Back to library

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Insulin Analog · Endocrine

Insulin Degludec (Tresiba)

Ultra-long-acting basal insulin with >42-hour duration.

FDA-Approved

Plain-Language Label Highlights

Brand names: Tresiba

What it's approved for

Type 1 and type 2 diabetes — once-daily ultra-long basal insulin (>42 hr duration).

A flat, ultra-long-acting basal insulin with flexible timing — generally lower nighttime lows than older basal insulins.

Common side effects
  • Hypoglycemia
  • Injection-site reactions
  • Weight gain
  • Upper respiratory infection
Serious risks to know
  • Severe hypoglycemia
  • Hypokalemia
  • Hypersensitivity reactions
  • Fluid retention if combined with thiazolidinediones
Who should avoid or use with extra caution
  • During hypoglycemia
  • Known degludec hypersensitivity

Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.

Mechanism of Action

Insulin analog with a hexadecanedioic acid side chain at LysB29 that forms soluble multi-hexamers at the injection site, releasing monomers slowly for flat, prolonged action.

Research Areas

Basal insulin therapy
Flexible dosing schedules
Reduced nocturnal hypoglycemia

Common Research Protocols

Once-daily SC

Once-daily subcutaneous dose; timing flexibility within 8–40 hours between doses.

Protocols summarized for educational reference from published research. Not dosing guidance.

Cited Research

[1]NEJM·2017

DEVOTE trial

Cardiovascular safety vs glargine with lower severe hypoglycemia.

Important Considerations

  • FDA-approved.
  • Steady state reached after ~3 days.

Explore more peptides

Educational Information Only — Not Medical Advice

All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.

Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.

Searching the library…

Ask the Library

Ask anything about peptides — answers come from our curated reference library with citations.

Find a pharmacy that carries Insulin Degludec (Tresiba)

Leave your details and a vetted partner pharmacy will reach out with availability and pricing.